WASHINGTON — Sens. John McCain (R., Ariz.) and Tammy Baldwin (D., Wis.) and Rep. Jan Schakowsky (D., Ill.) this week reintroduced the Fair Accountability and Innovative Research (FAIR) Drug Pricing Act, aimed at improving cost transparency for pharmaceutical price hikes. The FAIR Drug Pricing Act would require drug manufacturers to notify the Department of Health
ARLINGTON, Va. — The National Association of Chain Drug Stores (NACDS) sent a letter to all 100 U.S. senators last month ahead of a vote on an amendment that would allow Americans to purchase prescription drugs from Canada. In its letter, NACDS said that importation undermines the prescription drug safety net. “NACDS shares the goal
NEW YORK — Senate leaders have voiced concerns about a price surge for Mylan Inc.’s EpiPen, an epinephrine auto-injector for treating anaphylaxis, or potentially life-threatening allergic reactions. Sen. Chuck Grassley (R, Iowa), chairman of the Senate Judiciary Committee, and Sens. Susan Collins (R., Maine) and Claire McCaskill (D., Mo.), chairman and ranking member of the
DEERFIELD, Ill. — Walgreens Boots Alliance may have to divest up to 400 of the Rite Aid stores it is acquiring to satisfy antitrust regulations, analysts said. WBA is not publicly speculating on how many units it will have to shutter, said chief executive officer Stefano Pessina. “We have analyzed things very carefully,” he said
WASHINGTON — Two U.S. senators with oversight for antitrust issues have called on federal regulators to take a close look at Walgreens Boots Alliance Inc.’s $17.2 billion deal to acquire Rite Aid Corp. Sen. Mike Lee (R., Utah), chairman of the Senate Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights, and Sen. Amy Klobuchar
